Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients.
CT
FDG PET/CT
NSCLC
cfDNA concentration
cfDNA fragment size fractions
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
24
11
2020
accepted:
07
03
2021
pubmed:
3
4
2021
medline:
21
10
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
The aim of our study was to investigate the correlation between cfDNA concentration and fragment size fraction with FDG PET/CT- and CT-derived parameters in untreated NSCLC patient. Fifty-three patients diagnosed of locally advanced or metastatic NSCLC who had undergone FDG PET/CT, CT and cfDNA analysis prior to any treatment were included in this retrospective study. CfDNA concentration was measured by fluorometry and fragment size fractions were determined by microchip electrophoresis. [ CfDNA concentration showed a positive correlation with extrapulmonary MTV (r This study supports the hypothesis that cfDNA concentration and short cfDNA fragment size fraction reflect the tumour burden as well as metabolic activity in advanced NSCLC patients. This suggests their suitability as complementary tests for a more accurate diagnosis of tumour metabolic behaviour and to allow personalised therapies.
Identifiants
pubmed: 33797597
doi: 10.1007/s00259-021-05306-2
pii: 10.1007/s00259-021-05306-2
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3631-3642Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
pubmed: 30207593
pmcid: 30207593
Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 2017;7:1–7.
doi: 10.3389/fonc.2017.00193
Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI insight. 2018;3.
Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86.
doi: 10.1200/JCO.2012.45.2011
Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med. 2011;155:137–44.
doi: 10.7326/0003-4819-155-3-201108020-00003
Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2018;88:1–9.
doi: 10.1016/j.ejca.2017.10.029
Tissot C, Toffart A-C, Villar S, Souquet P-J, Merle P, Moro-Sibilot D, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015;46:1773–80.
doi: 10.1183/13993003.00676-2015
Spindler K-LG, Boysen AK, Pallisgård N, Johansen JS, Tabernero J, Sørensen MM, et al. Cell-free DNA in metastatic colorectal cancer: a systematic review and meta-analysis. Oncologist. 2017;22:1049–55.
doi: 10.1634/theoncologist.2016-0178
Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–209.
doi: 10.1056/NEJMoa1213261
Singh N, Gupta S, Pandey RM, Chauhan SS, Saraya A. High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement. Metastasis Poor Surviv Cancer Invest. 2015;33:78–85.
Winther-Larsen A, Fledelius J, Demuth C, Bylov CM, Meldgaard P, Sorensen BS. Early change in FDG-PET signal and plasma cell-free DNA level predicts erlotinib response in EGFR wild-type NSCLC patients. Transl Oncol. 2016;9:505–11.
doi: 10.1016/j.tranon.2016.09.003
Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, Kupis W, Rudzinski P, Langfort R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer. 2015;113:476–83.
doi: 10.1038/bjc.2015.225
Weng J-L, Atyah M, Zhou C-H, Ren N. Progress in quantitative technique of circulating cell free DNA and its role in cancer diagnosis and prognosis. Cancer Gene Ther. 2019;239:75–84.
doi: 10.1016/j.cancergen.2019.10.001
Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087.
doi: 10.1016/j.bdq.2019.100087
Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12:1–24.
doi: 10.1371/journal.pgen.1006162
Jiang P, Chan CWM, Chan KCA, Cheng SH, Wong J, Wong VWS, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015;112:E1317–25.
doi: 10.1073/pnas.1500076112
Mouliere F, Robert B, Peyrotte E, Del Rio M, Ychou M, Molina F, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011;6(9):e23418.
doi: 10.1371/journal.pone.0023418
Yamamoto Y, Uemura M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, et al. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. Oncotarget. 2018;9:20467–75.
doi: 10.18632/oncotarget.24943
Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, et al. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018;16:1–10.
doi: 10.1186/s12967-018-1677-2
Soliman SES, Alhanafy AM, Habib MSE, Hagag M, Ibrahem RAL. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem Biophys Reports. 2018;15:45–51.
doi: 10.1016/j.bbrep.2018.06.002
Lin J, Xie G, Liao G, Wang B, Yan M, Li H, et al. Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8:33884–96.
doi: 10.18632/oncotarget.13934
Infante JR, Cabrera J, Rayo JI, Cruz C, Serrano J, Moreno A, et al. 18F-FDG PET/CT quantitative parameters as prognostic factor in localized and inoperable lung cancer. Rev Esp Med Nucl Imagen Mol. 2020;39:353–9.
pubmed: 32605894
Zhu D, Wang L, Zhang H, Chen J, Wang Y, Byanju S, et al. Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: a systematic review and meta-analysis. Medicine. 2017;96:e7813.
doi: 10.1097/MD.0000000000007813
McEvoy AC, Warburton L, Al-Ogaili Z, Celliers L, Calapre L, Pereira MR, et al. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer. 2018;18:1–8.
doi: 10.1186/s12885-018-4637-6
Woff E, Kehagias P, Vandeputte C, Ameye L, Guiot T, Paesmans M, et al. Combining 18F-FDG PET/CT-based metabolically active tumor volume and circulating cell-free DNA significantly improves outcome prediction in chemorefractory metastatic colorectal cancer. J Nucl Med. 2019;60:1366–72.
doi: 10.2967/jnumed.118.222919
Vizza E, Corrado G, De Angeli M, Carosi M, Mancini E, Baiocco E, et al. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J Exp Clin Cancer Res. 2018;37:16.
doi: 10.1186/s13046-018-0688-4
Çelik F, Tan YZ, Özdemir S, Sılan F. Comparison of SUVmax values obtained from F-18 FDG PET/CT and cell-free DNA levels measured from plasma in oncology patients. Mol Imaging Radionucl Ther. 2019;28:46–52.
doi: 10.4274/mirt.galenos.2019.60352
Winther-Larsen A, Demuth C, Fledelius J, Madsen AT, Hjorthaug K, Meldgaard P, et al. Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. Br J Cancer. 2017;117:704–9.
doi: 10.1038/bjc.2017.215
Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E, et al. Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study. J Nucl Med. 2017;58:1764–9.
doi: 10.2967/jnumed.117.193201
Nygaard AD, Holdgaard PC, Spindler KLG, Pallisgaard N, Jakobsen A. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer. 2014;110:363–8.
doi: 10.1038/bjc.2013.705
Hu Z, Chen H, Long Y, Li P, Gu Y. The main sources of circulating cell-free DNA: apoptosis, necrosis and active secretion. Crit Rev Oncol Hematol. 2021;157:103166.
doi: 10.1016/j.critrevonc.2020.103166
Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, et al. The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol. 2009;4:679–83.
Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008;3:971–8.
doi: 10.1097/JTO.0b013e31818307a7
Cappabianca S, Porto A, Petrillo M, Greco B, Reginelli A, Ronza F, et al. Preliminary study on the correlation between grading and histology of solitary pulmonary nodules and contrast enhancement and [18F]fluorodeoxyglucose standardised uptake value after evaluation by dynamic multiphase CT and PET/CT. J Clin Pathol. 2011;64:114–9.
doi: 10.1136/jcp.2010.076562
Chiu C-H, Yeh Y-C, Lin K-H, Wu Y-C, Lee Y-C, Chou T-Y, et al. Histological subtypes of lung adenocarcinoma have differential 18F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan. J Thorac Oncol. 2011;6:1697–703.
doi: 10.1097/JTO.0b013e318226b677
Stewart CM, Tsui DWY. Circulating cell-free DNA for non-invasive cancer management. Cancer Gene Ther. 2018;228–229:169–79.
doi: 10.1016/j.cancergen.2018.02.005
Sorber L, Zwaenepoel K, Jacobs J, De Winne K, Goethals S, Reclusa P, et al. Circulating cell-free DNA and RNA analysis as liquid biopsy: optimal centrifugation protocol. Cancers (Basel). 2019;11:458.
doi: 10.3390/cancers11040458
Bronkhorst AJ, Aucamp J, Pretorius PJ. Cell-free DNA: Preanalytical variables. Clin Chim Acta. 2015;450:243–53.
doi: 10.1016/j.cca.2015.08.028
Shi J, Zhang R, Li J, Zhang R. Size profile of cell-free DNA: a beacon guiding the practice and innovation of clinical testing. Theranostics. 2020;10:4737–48.
doi: 10.7150/thno.42565
Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, De Ruysscher D, et al. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol. 2009;4:822–8.
doi: 10.1097/JTO.0b013e3181a97df7
Wang R-A, Li Q-L, Li Z-S, Zheng P-J, Zhang H-Z, Huang X-F, et al. Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med. 2013;17:205–11.
doi: 10.1111/j.1582-4934.2012.01663.x
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch R-D, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–65.
pubmed: 11245480
Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Oriuchi N, et al. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med. 2011;52:705–11.
doi: 10.2967/jnumed.111.087676